{
    "clinical_study": {
        "@rank": "77379", 
        "acronym": "SORT-OUT VIII", 
        "arm_group": [
            {
                "arm_group_label": "SYNERGY", 
                "arm_group_type": "Active Comparator", 
                "description": "Coronary implantatation of the SYNERGY everolimus-eluting stent"
            }, 
            {
                "arm_group_label": "Biomatrix Neoflex", 
                "arm_group_type": "Active Comparator", 
                "description": "Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to perform a randomised comparison between the SYNERGY and the\n      Biomatrix NeoFlex stents in treatment of unselected patients with ischemic heart disease."
        }, 
        "brief_title": "Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Ischemic Heart Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "SORT-OUT VIII is a randomised, multicenter, all-comer, two-arm, non-inferiority trial\n      comparing the everolimus-eluting SYNERGY stent versus the Biomatrix NeoFlex stent in\n      treatment of atherosclerotic coronary artery lesions.\n\n      Primary Endpoint:\n\n      Device-related Target Lesion Failure (TLF) hierarchically as cardiac death, non-index\n      procedure related acute myocardial infarction (AMI) not clearly related to another lesion\n      than the target lesion, or target lesion revascularisation (TLR) (new revascularization of\n      target lesion) (significant stenosis in the stent \u00b1 5 mm distal/proximal) by percutaneous\n      coronary intervention (PCI) or coronary artery bypass operation (CABG) within 12 months.\n\n      Secondary Endpoint:\n\n      Device-related target lesion failure hierarchically as cardiac death, non-index procedure\n      related acute myocardial infarction, not clearly related to another lesion than the target\n      lesion, or new target lesion revascularization by percutaneous coronary intervention or\n      coronary bypass operation at 2-5 years.\n\n      Patient-related combined endpoint hierarchically as all-cause death, non-index procedure\n      related acute myocardial infarction or all new revascularizations by percutaneous coronary\n      intervention or coronary bypass operation at 12, 24, 36, 48 and 60 months.\n\n      Individual above mentioned stent- or patient-related endpoints at 12, 24, 36, 48 and 60\n      months\n\n      MACE (combined endpoint as cardiac death, acute myocardial infarction or new\n      revascularization of the study vessel)\n\n      Stent thrombosis defined according to the Academic Research Consortium (ARC) criteria within\n      24 hours (acute), between 1 and 30 days (subacute), between 30 days and 12 months (late),\n      and after 12, 24, 36, 48 and 60 months (very late).\n\n      Device success rate defined as the frequency of a successful implantation with residual\n      stenosis < 20% of the study stent in all the stenoses scheduled to be treated.\n\n      Procedural success rate defined as the frequency of successful implantation with residual\n      stenosis <20% of the study stent in all the stenoses scheduled to be treated and without\n      serious complications (cardiac death, non-index procedure related acute myocardial\n      infarction related to target vessel or new revascularization of target lesion by\n      percutaneous coronary intervention or coronary bypass operation).\n\n      Inclusion criteria:\n\n      All patients aged \u226518 years who are eligible for treatment with one or several drug-eluting\n      coronary stents at one of the three heart centers in Odense, Skejby and Aalborg can be\n      included in the study.\n\n      Exclusion criteria Age < 18 years The patient does not wish to participate The patient is\n      not able to consent to randomization (eg intubated patients) The patient do not live in\n      Western Denmark The patient do not speak Danish The patient is already included in this\n      study The patient is participating in other stent studies Life expectancy <1 year Allergic\n      to Aspirin, clopidogrel, prasugrel or ticagrelor Allergic to everolimus or biolimus Only\n      implanted bare metal stents (BMS) Only performed plain old balloon angioplasty (POBA)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients aged \u226518 years who are eligible for treatment with one or several\n             drug-eluting coronary stents at one of the three heart centers in Odense, Skejby and\n             Aalborg can be included in the study.\n\n        Exclusion Criteria:\n\n          -  Age < 18 years\n\n          -  The patient does not wish to participate\n\n          -  The patient is not able to consent to randomization (eg intubated patients)\n\n          -  The patient do not live in West Denmark\n\n          -  The patient do not speak Danish\n\n          -  The patient is already included in this study\n\n          -  The patient is already participating in other stent studies\n\n          -  Life expectancy <1 year\n\n          -  Allergic to Aspirin, clopidogrel, prasugrel or ticagrelor\n\n          -  Allergic to everolimus or biolimus\n\n          -  Only implanted BMS\n\n          -  Only performed POBA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093845", 
            "org_study_id": "1-10-72-3-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Biomatrix Neoflex", 
                "description": "Percutaneous coronary intervention involving use of stent", 
                "intervention_name": "Biomatrix NeoFlex coronary stent", 
                "intervention_type": "Device", 
                "other_name": "Biolimus-eluting Biomatrix NeoFlex coronary stent"
            }, 
            {
                "arm_group_label": "SYNERGY", 
                "description": "Percutaneous coronary intervention involving use of stent", 
                "intervention_name": "SYNERGY stent", 
                "intervention_type": "Device", 
                "other_name": "Everolimus-eluting SYNERGY coronary stent"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Percutaneous coronary intervention", 
            "DES", 
            "Angina pectoris", 
            "Stent"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "michael.maeng@ki.au.dk", 
                "last_name": "Michael Maeng, MD", 
                "phone": "+45 7845 0000", 
                "phone_ext": "52042"
            }, 
            "contact_backup": {
                "email": "jens.lassen@ki.au.dk", 
                "last_name": "Jens F Lassen, MD", 
                "phone": "+45 7845 0000", 
                "phone_ext": "52031"
            }, 
            "facility": {
                "address": {
                    "city": "Skejby", 
                    "country": "Denmark", 
                    "state": "Aarhus N", 
                    "zip": "8200"
                }, 
                "name": "Aarhus University Hospital"
            }, 
            "investigator": {
                "last_name": "Michael Maeng, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Clinical Comparison of Everolimus-Eluting SYNERGY\u00ae and Biolimus-Eluting BioMatrix NeoFlex\u00ae Coronary Stents in Non-Selected Patients With Ischemic Heart Disease", 
        "overall_contact": {
            "email": "michael.maeng@ki.au.dk", 
            "last_name": "Michael Maeng, MD", 
            "phone": "+45 7845 0000", 
            "phone_ext": "52042"
        }, 
        "overall_contact_backup": {
            "email": "jens.lassen@ki.au.dk", 
            "last_name": "Jens F Lassen, MD", 
            "phone": "+45 7845 0000", 
            "phone_ext": "52031"
        }, 
        "overall_official": [
            {
                "affiliation": "Aarhus University Hospital, Skejby, Aarhus N", 
                "last_name": "Michael Maeng, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Cardiology, Aarhus University Hospital, Skejby, Denmark", 
                "last_name": "Jens F Lassen, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hierarchically as cardiac death, non-index procedure related acute myocardial infarction not clearly related to another lesion than the target lesion, or target lesion revascularisation (new revascularisation of target lesion revascularisation (significant stenosis in the stent =/+ 5 mm distal/proximal) by percutaneous coronary intervention or coronary artery bypass operation", 
            "measure": "Device-related target lesion failure", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093845"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aarhus University Hospital Skejby", 
            "investigator_full_name": "Michael M\u00e6ng", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Hierarchically as cardiac death, non-index procedure related acute myocardial infarction not clearly related to another lesion than the target lesion, or target lesion revascularisation (new revascularisation of target lesion revascularisation by percutaneous coronary intervention or coronary artery bypass operation", 
                "measure": "Device-related target lesion failure", 
                "safety_issue": "Yes", 
                "time_frame": "2, 3, 4 and 5 years"
            }, 
            {
                "description": "Hierarchically as all-cause death, non-index procedure related acute myocardial infarction, or all new revascularisation by percutaneous coronary intervention or coronary artery bypass operation", 
                "measure": "Patient-related combined endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "1, 2, 3, 4 and 5 year"
            }, 
            {
                "measure": "Individual above mentioned stent- or patient-related endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "1, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "Combined endpoint as cardiac death, acute myocardial infarction or new revascularisation of the study vessel", 
                "measure": "MACE", 
                "safety_issue": "Yes", 
                "time_frame": "1, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "Stent thrombosis according to the Academic Research Consortium definitions", 
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "Within 24 hours, between 1 and 30 days, between 30 days and 12 months and after 1, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "The frequency of a successful implantation with residual stenosis <20% of the study stent in all stenoses scheduled to be treated", 
                "measure": "Device success rate", 
                "safety_issue": "Yes", 
                "time_frame": "intraoperative"
            }
        ], 
        "source": "Aarhus University Hospital Skejby", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Boston Scientific Corporation", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Biosensors Europe SA", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Aarhus University Hospital Skejby", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}